The pressure builds for Emma Walmsley as GlaxoSmithKline misses Q1 projection, drops more cancer drugs
GlaxoSmithKline CEO Emma Walmsley is staying focused on the company’s split as earnings slide and Elliott Management lurks on the sidelines, threatening to launch one of its notorious activist attacks aimed to shake things up. And in a Q1 marked by a couple of major setbacks on the oncology side, R&D chief Hal Barron is doing some fine tuning of the pipeline that includes dropping two early stage candidates for cancer and Duchenne muscular dystrophy (DMD).
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 129,500+ biopharma pros reading Endpoints daily — and it's free.